Traduction de «for applications submitted » (Néerlandais → Français) :

TERMINOLOGIE

extracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur extracorporel de système d’hyperthermie de circulation extravasculaire

applicator voor aneurysmaclip
applicateur de clips d’anévrisme

applicator voor compressiekousen
enfile-bas de contention

applicator voor dermale anesthesie
applicateur dermique d’anesthésie locale

handbediende applicator voor brachytherapiesysteem voor oog
applicateur manuel de système de brachythérapie oculaire

applicator voor thermisch pulsatiesysteem voor ooglid
applicateur pour système de traitement thermique par impulsions sur les paupières

intracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur intracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor oesofageaal brachytherapiesysteem
applicateur manuel de système de brachythérapie pour l’œsophage

applicator voor oesofageaal brachytherapiesysteem met op afstand bedienbare afterloading
applicateur de système de brachythérapie pour l’œsophage à chargement différé à distance

applicator voor tandheelkundige hars
applicateur de matériau de restauration dentaire

TRADUCTIONS EN CONTEXTE

Veterinary medicines Unit For the fifth year in a row the number of applications closed for obtaining marketing authorisation (MA) within the Veterinary medicines Unit has exceeded the number of new applications submitted.
Veterinary medicines Unit For the fifth year in a row the number of applications closed for obtaining marketing authorisation (MA) within the Veterinary medicines Unit has exceeded the number of new applications submitted.

medicines for human use and veterinary medicines, raw materials (active ingredients) for pharmacists, establishment of retail pharmacies, medical devices) ●● Management of possible crisis situations ●● Coordination of the (inter)national representation of the FAMHP ●● The difference between the roles of “Communication” versus “Information” ●● Points of entry for applications submitted to
medicines for human use and veterinary medicines, raw materials (active ingredients) for pharmacists, establishment of retail pharmacies, medical devices) ●● Management of possible crisis situations ●● Coordination of the (inter)national representation of the FAMHP ●● The difference between the roles of “Communication” versus “Information” ●● Points of entry for applications submitted to

In 2007, the number of applications submitted in MeSeA on a weekly basis rose by approximately 30%.
In 2007, the number of applications submitted in MeSeA on a weekly basis rose by approximately 30%.

In 2007, 560 new complete applications were submitted, 24% of which were for phase I trials, while 1214 amendments to existing or current applications were also submitted.
In 2007, 560 new complete applications were submitted, 24% of which were for phase I trials, while 1214 amendments to existing or current applications were also submitted.

Submitted applications Validated applications Applications in “Parking”system Finalised applications
Submitted applications Validated applications Applications in “Parking”system Finalised applications

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.
Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.

The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.
The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.